China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that ...
GlaxoSmithKline has upped its expectations for the year after a strong performance by its vaccines division in the second quarter and the delay of a potential generic version of Advair in the US.